Leiden, January 27, 2025 — Leiden, Netherlands, January 27, 2025 — MIMETAS, a global leader in human disease modeling, has launched OrganoPlate UniFlow (UF), the first commercially available unidirectional, gravity-driven pumpless flow system for drug discovery and disease research. This innovative platform debuts as a key addition to MIMETAS’ service portfolio.
OrganoPlate UF addresses challenges in traditional flow systems by enabling physiologically accurate tissue models that replicate natural biological conditions. With unidirectional, gravity-driven flow, this system eliminates the need for external pumps, simplifying operation while enhancing model accuracy. Supporting up to 512 chips in a single setup, the technology is ideal for rigorous scientific studies and large-scale screening, accelerating research without compromising biological relevance.
Key Features of OrganoPlate UF Technology:
- Unidirectional flow: Improves modeling of vasculature for studies in cardiovascular, oncological, and immunological research.
- Pump-free, gravity-driven design: Simplifies operations while mimicking natural flow conditions.
- Scalable and compatible: Operates seamlessly with standard liquid handling and imaging equipment, enabling high-throughput analysis of hundreds or thousands of tissue models.
- Stable, long-term culture: Supports extended culture of complex tissues for chronic disease and therapeutic studies.
“The MIMETAS OrganoPlate has led the field in microphysiological cell culture for over 12 years,” said Bas Trietsch, MIMETAS co-founder. “With UniFlow, we’ve achieved unidirectional flow that mimics blood circulation while maintaining the ease of use, compatibility, and throughput that make our technology exceptional.”
OrganoPlate UF is already integrated into MIMETAS’ liver, lung, brain, vasculature, and tumor models and is used to study immunological, cardiovascular, and metabolic diseases, as well as cancer. This platform is now available as part of MIMETAS’ service offerings.